Stockscreener 앱 받기
4.88
8.69%
0.39
전일 마감가:
$4.49
열려 있는:
$4.88
하루 거래량:
49,073
Relative Volume:
0.13
시가총액:
$217.12M
수익:
-
순이익/손실:
$-197.68M
주가수익비율:
-1.2979
EPS:
-3.76
순현금흐름:
$-158.88M
1주 성능:
+16.65%
1개월 성능:
+79.78%
6개월 성능:
+25.00%
1년 성능:
+29.73%
1일 변동 폭
$4.84
$4.91
1주일 범위
$3.96
$5.04
52주 변동 폭
$1.92
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
명칭
Kodiak Sciences Inc
전화
650-281-0850
주소
1200 PAGE MILL RD, PALO ALTO, CA
KOD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
4.84 | 217.12M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.56 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.55 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.14 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.81 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2023-12-11 | 재개 | Goldman | Sell |
| 2023-11-17 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-24 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-15 | 개시 | CapitalOne | Overweight |
| 2022-08-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-02-11 | 개시 | Goldman | Buy |
| 2022-02-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-03-12 | 개시 | Evercore ISI | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-02-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-11-30 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-11-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-03 | 개시 | Goldman | Buy |
| 2020-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-02-06 | 개시 | SunTrust | Buy |
| 2020-01-08 | 개시 | ROTH Capital | Buy |
| 2020-01-03 | 개시 | Jefferies | Buy |
| 2019-12-24 | 개시 | JP Morgan | Overweight |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-20 | 개시 | Chardan Capital Markets | Buy |
| 2018-10-29 | 개시 | Barclays | Overweight |
| 2018-10-29 | 개시 | BofA/Merrill | Buy |
| 2018-10-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Advances Retinal Therapies with Promising Pipeline - TipRanks
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Cuts Losses by 26%, Advances Two Phase 3 Trials with $168M War Chest - Stock Titan
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? - Insider Monkey
Diabetic Macular Edema Pipeline 2025: Therapies Under - openPR
Kodiak Sciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Critical Contrast: Metagenomi (NASDAQ:MGX) & Kodiak Sciences (NASDAQ:KOD) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - Stock Titan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise - The Globe and Mail
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
Kodiak Sciences Inc (KOD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kodiak Sciences Inc 주식 (KOD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
0.47%
3.97%
자본화:
|
볼륨(24시간):